phil lempert: it's affordability. it's convenience. it's not having a lot of waste. people are more concerned about waste than ever before.
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people.
.
.
.
.
.mumbai indians beat kings xi punjab by 3 runs
.
of all car-t cell trials registered since 2001, more than half are being conducted in china.
.